"Citalopram" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
Descriptor ID |
D015283
|
MeSH Number(s) |
D02.092.831.170 D02.626.320 D03.633.100.127.187
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Citalopram".
Below are MeSH descriptors whose meaning is more specific than "Citalopram".
This graph shows the total number of publications written about "Citalopram" by people in this website by year, and whether "Citalopram" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2008 | 1 | 1 | 2 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 2 | 0 | 2 |
2014 | 2 | 0 | 2 |
2015 | 2 | 0 | 2 |
2017 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Citalopram" by people in Profiles.
-
Disruption of lipid-raft localized Gas/tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds. Neuropsychopharmacology. 2018 06; 43(7):1481-1491.
-
Double-blind switch study of vilazodone in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2017 05; 32(3):121-126.
-
Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism. J Child Adolesc Psychopharmacol. 2015 Aug; 25(6):467-74.
-
Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study. Neuropsychopharmacology. 2016 Jan; 41(2):590-7.
-
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014 Aug; 78(2):373-83.
-
Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy. J Neuropsychiatry Clin Neurosci. 2014; 26(4):323-8.
-
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology. 2013 Sep; 38(10):1921-8.
-
Prevention of poststroke apathy using escitalopram or problem-solving therapy. Am J Geriatr Psychiatry. 2013 Sep; 21(9):855-62.
-
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012 Apr; 22(4):247-53.
-
Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. Stroke. 2011 Nov; 42(11):3281-3.